Loading…
BioAtla, Inc. is projected to rise to $3.75 by 2027, a +15% move from its current price of $3.26. BCAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.12 | $3.26 | $3.41 | 0.00% |
| Aug 6 | $3.06 | $3.26 | $3.47 | -0.01% |
| Aug 7 | $3.01 | $3.26 | $3.52 | -0.01% |
| Aug 8 | $2.98 | $3.26 | $3.57 | -0.01% |
| Aug 9 | $2.95 | $3.26 | $3.61 | -0.02% |
| Aug 10 | $2.92 | $3.26 | $3.64 | -0.02% |
| Aug 11 | $2.89 | $3.26 | $3.67 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.89 | $3.26 | $3.67 | -0.03% |
| Week 2 | $2.75 | $3.26 | $3.86 | -0.05% |
| Week 3 | $2.65 | $3.26 | $4.01 | -0.08% |
| Week 4 | $2.56 | $3.26 | $4.13 | -0.10% |
| Week 5 | $2.49 | $3.26 | $4.25 | -0.13% |
| Week 6 | $2.43 | $3.25 | $4.36 | -0.15% |
| Week 7 | $2.37 | $3.25 | $4.46 | -0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioAtla, Inc. is a clinical-stage biopharmaceutical company that develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.
The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. (BCAB) is a healthcare stock currently priced at $3.39. It holds a market cap of $5.63M and is ranked 5060 by its market position. The stock currently trades with a public market presence and a defined price point, forming part of the biotechnology/healthcare sector with a focus on CAB antibody-drug conjugates.
Forecasts indicate a variable long-term path, with 2026 showing a neutral stance and 2033 onward entering bullish territory, culminating in a 2050 average price of $7.89 and a max of $18.14; these figures reflect estimates and are not guaranteed.
A major floor 28.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 40.5% above — a clean break opens room to run.
A major ceiling 160.7% above — clearing it would confirm fresh momentum.
Key BCAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.36 | Sell | $3.36 | Sell |
| MA 10 | $3.44 | Sell | $3.47 | Sell |
| MA 20 | $3.72 | Sell | $3.60 | Sell |
| MA 50 | $3.70 | Sell | $4.06 | Sell |
| MA 100 | $4.77 | Sell | $6.50 | Sell |
| MA 200 | $16.00 | Sell | $12.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.33 | Neutral |
| Stoch RSI (14) | 13.61 | Buy |
| CCI (20) | -98.92 | Neutral |
| Williams %R (14) | -93.27 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -22.77 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 6.73 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 42.07 | Neutral |
| Momentum (10) | -0.66 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 3.30 | Sell |
| ADX (14) | 13.27 | Neutral |
| ATR (14) | 0.17 | Info |
The near-term technical picture is Bearish. The RSI14 is 40, indicating modest weakness. The 50-day simple moving average sits at $3.82, while the 200-day simple moving average is $17.39. The stock has support at $3.39 and resistance at $4.58. In the last 30 days, the price has traded within a range of $2.46 to $4.67.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.22 | $3.26 | $4.41 | 0% | Neutral | |
| $2.82 | $3.75 | $5.38 | +15% | Neutral | |
| $2.21 | $3.10 | $4.71 | -5% | Neutral | |
| $2.05 | $3.00 | $4.75 | -8% | Neutral | |
| $2.05 | $3.10 | $5.10 | -5% | Neutral | |
| $1.82 | $2.86 | $4.86 | -12% | Neutral | |
| $2.37 | $3.86 | $6.72 | +18% | Neutral | |
| $2.54 | $4.27 | $7.62 | +31% | Bullish | |
| $2.34 | $4.04 | $7.39 | +24% | Bullish | |
| $2.52 | $4.48 | $8.36 | +37% | Bullish | |
| $2.82 | $5.79 | $11.77 | +78% | Bullish | |
| $3.41 | $7.59 | $17.42 | +133% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.22 | $3.26 | $4.01 | +0.00% |
| September 2026 | $2.79 | $3.36 | $4.21 | +3.13% |
| October 2026 | $2.67 | $3.25 | $4.14 | -3.36% |
| November 2026 | $2.59 | $3.19 | $4.12 | -1.89% |
| December 2026 | $2.72 | $3.38 | $4.41 | +5.90% |
Click any year to see its month-by-month BCAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCAB is projected to trade between $3.22 and $4.41, averaging $3.26 — a potential gain of 0% from today's $3.26. A consolidation phase looks the most probable path here.
BioAtla, Inc.'s 2027 outlook centres on $3.75, within a $2.82 to $5.38 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2028, BCAB could reach as high as $4.71, with a base case around $3.10 and support toward $2.21 — roughly -5% from $3.26. A consolidation phase looks the most probable path here.
Expect BCAB to range from $2.05 to $4.75 through 2029. The $3.00 average target implies a -8% move from current prices. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
The BCAB price prediction for 2030 points to an average of $3.10 (low $2.05, high $5.10) — a potential decline of -5% on today's $3.26. A consolidation phase looks the most probable path here.
In 2031, BCAB is projected to trade between $1.82 and $4.86, averaging $2.86 — a potential decline of -12% from today's $3.26. That is -8% versus the projected 2030 average. Price action looks broadly range-bound.
BioAtla, Inc.'s 2032 outlook centres on $3.86, within a $2.37 to $6.72 range. That is up +35% on the projected 2031 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, BCAB could reach as high as $7.62, with a base case around $4.27 and support toward $2.54 — roughly +31% from $3.26. Momentum favours further upside here.
Expect BCAB to range from $2.34 to $7.39 through 2034. The $4.04 average target implies a +24% move from current prices. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCAB price prediction for 2035 points to an average of $4.48 (low $2.52, high $8.36) — a potential gain of +37% on today's $3.26. Momentum favours further upside here.
In 2040, BCAB is projected to trade between $2.82 and $11.77, averaging $5.79 — a potential gain of +78% from today's $3.26. That is up +29% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioAtla, Inc.'s 2050 outlook centres on $7.59, within a $3.41 to $17.42 range. That is up +31% on the projected 2040 average. That marks a +133% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCAB today (≈ 306.748466 BCAB) could be worth
$2,327.24
+$1,327.24 (+133%) by 2050 · US Dollar
Based on the average projected BCAB price of $7.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCABwould be worth at today's price.
$1,000 invested in BCAB on Jul 31, 2025 (≈ 55.710304 BCAB) would be worth
$181.62
-$818.38 (-81.8%) today · 0.18× · US Dollar
Based on a BCAB entry price of $17.95 vs. today's $3.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.37 | $967.36 | -3.3% |
| 1 month ago | $4.09 | $798.04 | -20.2% |
| 3 months ago | $4.27 | $763.47 | -23.7% |
| 6 months ago | $8.65 | $376.88 | -62.3% |
| 1 year ago | $17.95 | $181.62 | -81.8% |
| All time (5.0y) ago | $2,011.5 | $1.62 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCAB forecast.
Our base-case forecast reaches $6.50 around 2050.
Implied market cap at $6.50: $10.79M
The multi-year forecast shows a staged shift from neutral in the near term to bullish in the longer term. The 2033 avg price is $4.40 with a max of $8.08 and a 29.9% ROI, followed by 2034 with an avg of $4.24 and a 25.1% ROI. By 2035 the avg is $4.70 with a 38.7% ROI, and sentiment remains BULLISH.
The forecast turns strongly bullish by 2040, with an avg of $6.03, a max of $12.66 and a 77.8% ROI, continuing to 2050 with an avg of $7.89, a max of $18.14 and a 132.7% ROI. Earlier years show negative ROIs (e.g., 2028 -5.3%, 2029 -8.1%, 2030 -7.2%, 2031 -12.8%), while 2026 is neutral with a 0% ROI. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
2030 Avg price: $3.15; min $2.02; max $5.29; ROI -7.2%; sentiment NEUTRAL.
The forecast shows neutral in 2026 with 0% ROI, but positive ROIs in later years (2033 29.9%; 2040 77.8%; 2050 132.7%), and negative ROIs in 2028-2031, so outcomes are uncertain.
Yes. The 2040 max is $12.66 and the 2050 max is $18.14, which exceed $10.
Current price: $3.39; Market cap: $5.63M.
Bearish sentiment; RSI 14 at 40. The 50-day MA is $3.82 and the 200-day MA is $17.39. Support is at $3.39 and resistance at $4.58. The 30-day range is $2.46 to $4.67.
BioAtla, Inc. Community Discussion
0Share your BioAtla, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.